$EXEL
EXELIXIS, INC. Stock $exel

$exel Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000093976717000069 Filed on May 01, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$80.89M	$15.43M
YoY Change	424.32%	64.33%
Cost Of Revenue	$3.203M	$685.0K
YoY Change	367.59%	-10.57%
Gross Profit	$65.67M	$8.414M
YoY Change	680.53%	-2.41%
Gross Profit Margin	81.19%	54.54%
Selling, General & Admin	$34.29M	$34.86M
YoY Change	-1.63%	265.72%
% of Gross Profit	52.21%	414.27%
Research & Development	$23.21M	$28.93M
YoY Change	-19.76%	29.82%
% of Gross Profit	35.34%	343.78%
Depreciation & Amortization	$281.0K	$229.0K
YoY Change	22.71%	-22.9%
% of Gross Profit	0.43%	2.72%
Operating Expenses	$60.70M	$64.56M
YoY Change	-5.98%	100.83%
Operating Profit	$20.19M	-$49.14M
YoY Change	-141.08%	115.88%
Interest Expense	$4.420M	$10.29M
YoY Change	-57.05%	-17.04%
% of Operating Profit	21.9%
Other Income/Expense, Net	-$3.352M	-$10.09M
YoY Change	-66.77%	-18.71%
Pretax Income	$16.83M	-$59.22M
YoY Change	-128.42%	68.25%
Income Tax	$134.0K	$0.00
% Of Pretax Income	0.8%
Net Earnings	$16.70M	-$59.22M
YoY Change	-128.2%	78.14%
Net Earnings / Revenue	20.65%	-383.89%
Basic Earnings Per Share	$0.06	-$0.26
Diluted Earnings Per Share	$0.05	-$0.26
COMMON SHARES
Basic Shares Outstanding	290.9M shares	228.3M shares
Diluted Shares Outstanding	309.5M shares	228.3M shares

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$424.3M	$322.1M
YoY Change	31.73%	200.47%
Cash & Equivalents	$183.2M	$141.6M
Short-Term Investments	$241.1M	$45.20M
Other Short-Term Assets	$6.300M	$4.800M
YoY Change	31.25%	-57.52%
Inventory	$3.304M	$2.472M
Prepaid Expenses
Receivables	$34.10M	$10.10M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$468.0M	$339.5M
YoY Change	37.85%	171.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.594M	$1.813M
YoY Change	43.08%	-15.99%
Goodwill	$63.68M	$63.68M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$47.40M	$82.90M
YoY Change	-42.82%	1.59%
Other Assets	$1.251M	$2.068M
YoY Change	-39.51%	-73.39%
Total Long-Term Assets	$119.0M	$153.1M
YoY Change	-22.24%	-3.06%
TOTAL ASSETS
Total Short-Term Assets	$468.0M	$339.5M
Total Long-Term Assets	$119.0M	$153.1M
Total Assets	$587.0M	$492.5M
YoY Change	19.18%	74.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.649M	$5.657M
YoY Change	-17.82%	334.15%
Accrued Expenses	$53.60M	$16.14M
YoY Change	232.2%	-47.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$113.3M	$27.50M
YoY Change	312.0%	574.85%
Total Short-Term Liabilities	$202.3M	$101.1M
YoY Change	100.15%	72.23%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$361.2M
YoY Change	-100.0%	-0.88%
Other Long-Term Liabilities	$3.707M	$1.317M
YoY Change	181.47%	-55.52%
Total Long-Term Liabilities	$3.707M	$362.5M
YoY Change	-98.98%	-1.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$202.3M	$101.1M
Total Long-Term Liabilities	$3.707M	$362.5M
Total Liabilities	$467.2M	$648.5M
YoY Change	-27.95%	50.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.967B	-$1.998B
YoY Change	-1.59%	10.87%
Common Stock	$292.0K	$228.0K
YoY Change	28.07%	16.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$119.8M	-$156.0M
YoY Change
Total Liabilities & Shareholders Equity	$587.0M	$492.5M
YoY Change	19.18%	74.08%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	$16.70M	-$59.22M
YoY Change	-128.2%	78.14%
Depreciation, Depletion And Amortization	$281.0K	$229.0K
YoY Change	22.71%	-22.9%
Cash From Operating Activities	$68.86M	$156.8M
YoY Change	-56.09%	-447.8%
INVESTING ACTIVITIES
Capital Expenditures	$804.0K	$682.0K
YoY Change	17.89%	2100.0%
Acquisitions
YoY Change
Other Investing Activities	$35.30M	-$19.00M
YoY Change	-285.79%	-138.08%
Cash From Investing Activities	$34.50M	-$19.69M
YoY Change	-275.28%	-139.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$37.00K
YoY Change
Debt Paid & Issued, Net	$80.00M
YoY Change
Cash From Financing Activities	-$71.87M	-$1.877M
YoY Change	3728.88%	764.98%
NET CHANGE
Cash From Operating Activities	$68.86M	$156.8M
Cash From Investing Activities	$34.50M	-$19.69M
Cash From Financing Activities	-$71.87M	-$1.877M
Net Change In Cash	$31.49M	$135.2M
YoY Change	-76.71%	2845.3%
FREE CASH FLOW
Cash From Operating Activities	$68.86M	$156.8M
Capital Expenditures	$804.0K	$682.0K
Free Cash Flow	$68.05M	$156.1M
YoY Change	-56.41%	-446.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-29
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000939767
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	292512348	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	EXELIXIS, INC.
CY2017Q1	dei	Trading Symbol TradingSymbol	exel
CY2016Q4	exel	Accrued Clinical Liabilities Current AccruedClinicalLiabilitiesCurrent	14131000	USD
CY2017Q1	exel	Accrued Clinical Liabilities Current AccruedClinicalLiabilitiesCurrent	14478000	USD
CY2016Q4	exel	Cash Cash Equivalentsand Availableforsale Securities CashCashEquivalentsandAvailableforsaleSecurities	479554000	USD
CY2017Q1	exel	Cash Cash Equivalentsand Availableforsale Securities CashCashEquivalentsandAvailableforsaleSecurities	475774000	USD
CY2016Q4	exel	Cash Cash Equivalentsand Availableforsale Securities Amortized Cost Basis CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis	479862000	USD
CY2017Q1	exel	Cash Cash Equivalentsand Availableforsale Securities Amortized Cost Basis CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis	475992000	USD
CY2016Q4	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Gain Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments	14000	USD
CY2017Q1	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Gain Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments	37000	USD
CY2016Q4	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Loss Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments	322000	USD
CY2017Q1	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Loss Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments	255000	USD
CY2017Q1	exel	Debt Collateral Number Of Affiliate Banks DebtCollateralNumberOfAffiliateBanks	1	affiliate
CY2017Q1	exel	Debt Collateral Number Of Required Investment Accounts DebtCollateralNumberOfRequiredInvestmentAccounts	1	account
CY2017Q1	exel	Excess Tax Benefits Sharebased Compensation ExcessTaxBenefitsSharebasedCompensation	900000	USD
CY2016Q1	exel	Increase Decrease Accrued Clinical Liabilities IncreaseDecreaseAccruedClinicalLiabilities	-1936000	USD
CY2017Q1	exel	Increase Decrease Accrued Clinical Liabilities IncreaseDecreaseAccruedClinicalLiabilities	347000	USD
CY2016Q1	exel	Increase Decreasein Accrued Collaboration Liability IncreaseDecreaseinAccruedCollaborationLiability	3736000	USD
CY2017Q1	exel	Increase Decreasein Accrued Collaboration Liability IncreaseDecreaseinAccruedCollaborationLiability	0	USD
CY2017Q1	exel	Numberof Productsin Commercial Market NumberofProductsinCommercialMarket	3	product
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6565000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4649000	USD
CY2016Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	20334000	USD
CY2017Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	14490000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-416000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-326000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2072591000	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2086483000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11185000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4713000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3161000	USD
CY2017Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	89000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	120372000	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	35286000	shares
CY2016Q4	us-gaap	Assets Assets	595739000	USD
CY2017Q1	us-gaap	Assets Assets	586980000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	469001000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	467950000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	459966000	USD
CY2017Q1	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	456956000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	459966000	USD
CY2017Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	456956000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	37000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	322000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	255000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	460274000	USD
CY2017Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	457174000	USD
CY2017Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	184400000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	45353000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	411603000	USD
CY2016Q1	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2017Q1	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2017Q1	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	96	investment
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	141634000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	276882000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	151686000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	183179000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	135248000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	31493000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	289923798	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	292302330	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	289923798	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	292302330	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	290000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	292000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-59033000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	16790000	USD
CY2016Q1	us-gaap	Contracts Revenue ContractsRevenue	6328000	USD
CY2017Q1	us-gaap	Contracts Revenue ContractsRevenue	12010000	USD
CY2016Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	109122000	USD
CY2017Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	113349000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	685000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3203000	USD
CY2017Q1	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	19665000	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	30662000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	237094000	USD
CY2017Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	261236000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	229000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	281000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2016Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-200000	USD
CY2017Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-100000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	63684000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	63684000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-59223000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	16834000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	134000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	4956000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-6541000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-744000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1916000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	198802000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	35139000	USD
CY2016Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2413000	USD
CY2017Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-5844000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-144000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-34000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-241000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	19000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2367000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	10926000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	985000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	881000	USD
CY2016Q1	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	-2004000	USD
CY2017Q1	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	-3504000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	10290000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	4420000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	738000	USD
CY2017Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	774000	USD
CY2016Q4	us-gaap	Inventory Gross InventoryGross	3944000	USD
CY2017Q1	us-gaap	Inventory Gross InventoryGross	3928000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	3338000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	3304000	USD
CY2016Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	606000	USD
CY2017Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	624000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	863000	USD
CY2017Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	692000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2343000	USD
CY2017Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	2462000	USD
CY2017Q1	us-gaap	Inventory Write Down InventoryWriteDown	500000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	506421000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	467230000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	595739000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	586980000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	268786000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	202287000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	189122000	USD
CY2017Q1	us-gaap	Long Term Debt LongTermDebt	113349000	USD
CY2016Q4	us-gaap	Long Term Investments LongTermInvestments	55601000	USD
CY2017Q1	us-gaap	Long Term Investments LongTermInvestments	47351000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1877000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-71868000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19685000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	34503000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	156810000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	68858000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-59223000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	16700000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-59223000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	16643000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-59223000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	16646000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10088000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3352000	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	80000000	USD
CY2017Q1	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2017Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	64562000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	60701000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-49135000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	20186000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	18969000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	24659000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1232000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1251000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	190000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	90000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	541000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3707000	USD
CY2016Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-440000	USD
CY2017Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-680000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	202000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1068000	USD
CY2016Q1	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
CY2017Q1	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
CY2016Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	1936000	USD
CY2017Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	2068000	USD
CY2016Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1914000	USD
CY2017Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1543000	USD
CY2016Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	49235000	USD
CY2017Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	124494000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	682000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	808000	USD
CY2016Q1	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	2004000	USD
CY2017Q1	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	3504000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5416000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6297000	USD
CY2016Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	30108000	USD
CY2017Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	122507000	USD
CY2016Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	0	USD
CY2017Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-80000000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	17000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	37294000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	107000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	37000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9675000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2071000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2594000	USD
CY2016Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	40444000	USD
CY2017Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	34076000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28926000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23210000	USD
CY2016Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	4150000	USD
CY2017Q1	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	4150000	USD
CY2016Q1	us-gaap	Restructuring Charges RestructuringCharges	94000	USD
CY2017Q1	us-gaap	Restructuring Charges RestructuringCharges	28000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1983147000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1966699000	USD
CY2016Q1	us-gaap	Revenues Revenues	15427000	USD
CY2017Q1	us-gaap	Revenues Revenues	80887000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	9099000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	68877000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34857000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34260000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11185000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4713000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	16456810	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.02
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	141021	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	288120	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	377392000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24999665	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	22849406	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.91
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.15
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.29
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.23
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.16
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	290400000	USD
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y11M8D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y5M15D
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	268117000	USD
CY2017Q1	us-gaap	Short Term Investments ShortTermInvestments	241094000	USD
CY2017Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2297358	shares
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	89318000	USD
CY2017Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	119750000	USD
CY2016Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	USD
CY2017Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	57000	USD
CY2016Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	0	USD
CY2017Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	-3000	USD
CY2016Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2017Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	18665000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	228304000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	309535000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	228304000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	290870000	shares
CY2017Q1	us-gaap	Fiscal Period FiscalPeriod	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:inherit;font-size:10pt;">. Fiscal year 2017 will end on December 29, 2017 and fiscal year 2016 ended on December 30, 2016. For convenience, references in this report as of and for the fiscal periods ended March 31, 2017 and April 1, 2016, and as of and for the fiscal years ended December 29, 2017 and December 30, 2016, are indicated as being as of and for the periods ended March 31, 2017 and March 31, 2016, and the years ended December 31, 2017 and December 31, 2016, respectively.</font><font style="font-family:inherit;font-size:10pt;"> </font></div></div>
CY2017Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to current period presentation. We reclassified </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> in accrued product sales discounts payable to our customers as of December 31, 2016 from Other current liabilities to Trade and other receivables in the accompanying Condensed Consolidated Balance Sheets. We have also reclassified the related balances between the Changes in assets and liabilities line items in the accompanying Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2016 to conform the presentation of those line items to the corresponding presentation of assets and liabilities in our accompanying Condensed Consolidated Balance Sheets.</font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of our condensed consolidated financial statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, including deductions from revenues (such as rebates, chargebacks, sales returns and sales allowances), the period of performance, identification of deliverables and evaluation of milestones with respect to our collaborations, the amounts of revenues and expenses under our profit and loss sharing agreement, recoverability of inventory, certain accrued liabilities including accrued clinical trial liability, and stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000939767-17-000069-index-headers.html	Edgar Link	pending
0000939767-17-000069-index.html	Edgar Link	pending
0000939767-17-000069.txt	Edgar Link	pending
0000939767-17-000069-xbrl.zip	Edgar Link	pending
exel-20170331.xml	Edgar Link	completed
exel-20170331.xsd	Edgar Link	pending
exel-20170331_cal.xml	Edgar Link	unprocessable
exel-20170331_def.xml	Edgar Link	unprocessable
exel-20170331_lab.xml	Edgar Link	unprocessable
exel-20170331_pre.xml	Edgar Link	unprocessable
exel2017033110-q.htm	Edgar Link	pending
exel20170331exhibit101.htm	Edgar Link	pending
exel20170331exhibit102.htm	Edgar Link	pending
exel20170331exhibit103.htm	Edgar Link	pending
exel20170331exhibit121.htm	Edgar Link	pending
exel20170331exhibit311.htm	Edgar Link	pending
exel20170331exhibit312.htm	Edgar Link	pending
exel20170331exhibit321.htm	Edgar Link	pending
exhibit101cabochemstructure.jpg	Edgar Link	pending
exhibit101takedalogo.jpg	Edgar Link	pending
exhibit102bmslogoa01.jpg	Edgar Link	pending
exhibitexelixislogo.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EXEL
EXELIXIS, INC. Stock $exel

2017 Q1 Form 10-Q Financial Statement

#000093976717000069 Filed on May 01, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EXEL EXELIXIS, INC. Stock $exel

2017 Q1 Form 10-Q Financial Statement

#000093976717000069 Filed on May 01, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EXEL
EXELIXIS, INC. Stock $exel